Cleary Gottlieb is advising Merck KGaA (Merck), a leading science and technology company, in the divestment of its allergy business Allergopharma to Dermapharm Holding SE (Dermapharm).
The transaction encompasses the Allergopharma business in Europe and Asia, including the therapeutic and diagnostic product portfolio as well as the production site in Reinbek near Hamburg (Germany).
The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions.
Allergopharma is a leader in allergen-specific immunotherapy of type 1 allergies, such as hay fever or allergic asthma.
Dermapharm is a leading manufacturer of off-patent branded medicines for selected markets in Germany.